Featured Content
View Full Article

New Cholesterol Treatment Guideline: Implications for Pharmacy Practice 6/19/2014

The 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol takes an evidence-based approach that stresses the reduction of cardiovascular risk.

Related Content

Behavioral Health Management: Opportunities for Intervention With Health Information Technologies

Health information technology has the potential to impact medication management, care coordination, and management of comorbid conditions in behavioral health.

Management of Common Oral Sores

The two most common types are canker sores and cold sores.

Scleroderma: Managing Systemic Sclerosis and Its Complications

The treatment of systemic sclerosis and its complications is complex and requires careful evaluation and collaboration between the pharmacist and other practitioners.

Disorders Associated With Celiac Disease

With celiac disease, the risk of developing other autoimmune and nonautoimmune disorders increases.

Pharmaceutical Care of Celiac Disease

Celiac disease, also known as gluten-sensitive enteropathy or sprue, is a chronic autoimmune disorder caused by a genetic intolerance to gluten.

STATIN

View Full Article

The Pleiotropic Effects of Statins: A Panacea? 10/17/2008

Landmark clinical trials such as the Scandinavian Simvastatin Survival Study (also known as 4S), the West of Scotland Coronary Prevention Study, the Long-Term Intervention with Pravastatin in Ischemic Disease Trial, the Heart Protection Study, and the Cholesterol and Recurrent Events Trial have solidified the utility of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, for primary and secondary prevention of cardiovascular disease.

Drug Combination Slows Prostate Cancer Growth 7/18/2008

Attendees at a meeting of the American Association for Cancer Research learned that while the results of a study conducted at Rutgers University in New Brunswick, NJ, showed that atorva­ statin (Lipitor) and celecoxib (Celebrex) individually slowed tumor progression from androgen-dependent to androgen-independent status, the two drugs combined had additive growth-inhibiting activity compared with either drug alone.

Statins for the Treatment of Sepsis 2/20/2008

1 Approximately 750,000 patients develop sepsis each year.

Pharmacologic Management of Post-Acute Coronary Syndrome 2/20/2007

Acute coronary syndromes (ACS) include the spectrum of clinical conditions ranging from unstable angina to non-Q-wave myocardial infarction (MI) and Q-wave MI.

Advertisement